NovoCure Limited (NVCR) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

Earnings Reports

• NovoCure (NVCR) Q2 2026: Optune Pax Scripts Surge 200%, Catalyzing Multi-Indication Growth Trajectory
  July 23, 2026
• NovoCure (NVCR) Q1 2026: Optune Pax Launch Drives 868 Provider Certifications, Accelerating Oncology Pipeline
  April 30, 2026
• NovaCure (NVCR) Q4 2025: Non-GBM Portfolio Targets $25M as Platform Expansion Accelerates
  February 26, 2026
• NovoCure (NVCR) Q3 2025: GBM Patient Base Hits 4,277 as Platform Expansion Prioritizes Four Indications
  October 30, 2025
• Novocure (NVCR) Q2 2025: Optune Lua Drives $2.4M New Revenue as Multi-Indication Pipeline Accelerates
  July 24, 2025
• Novocure (NVCR) Q1 2025: 93 Unique Lung Cancer Prescribers Signal Durable Multi-Indication Pivot
  July 07, 2025

Browse all companies